SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $624,441,478 |
| Positions | 45 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $205,115,856 | 2,104,184 |
| CG ONCOLOGY INC | CGON | COM | $99,395,255 | 1,398,948 |
| ORUKA THERAPEUTICS INC | ORKA | COM | $72,369,552 | 760,424 |
| JADE BIOSCIENCES INC | JBIO | COM NEW | $37,789,732 | 1,700,708 |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $27,912,500 | 550,000 |
| PERSPECTIVE THERAPEUTICS INC | CATX | COM NEW | $21,482,997 | 6,299,999 |
| AKTIS ONCOLOGY INC | AKTS | COM | $15,605,766 | 484,200 |
| PALVELLA THERAPEUTICS INC NE | PVLA | COM | $10,697,400 | 70,000 |
| MOBIA MED INC | MOBI | COMMON STOCK | $10,696,979 | 798,282 |
| REPLIGEN CORP | RGEN | COM | $10,615,032 | 77,800 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.